NeuroPace(NASDAQ) NPCE

NeuroPace, Inc. helps people with epilepsy stop their seizures.

Their brain-responsive system stops seizures at the source in real time.

The technology treats adults whose seizures medicine cannot control.

Stopping Seizures at the Source

• RNS System: Brain-responsive neuromodulation system that monitors brain activity and stops seizures with electrical pulses.
• Implantable Components: Neurostimulator and leads that detect abnormal electrical patterns at the seizure source.
• Monitoring Hardware: Patient monitor and physician tablet used to manage care and program implanted devices.
• Data Platforms: Secure online databases and software that provide clinicians with personalized patient activity reports.

Strategic Steps and Clinical Expansion

• Filed for label expansion in December 2025 to treat patients with drug-resistant idiopathic generalized epilepsy.
• Entered a collaboration with Rapport Therapeutics in June 2025 to provide clinical data and biomarker monitoring services.
• Partnered with the FDA in 2025 to use real-world data for pediatric epilepsy studies.
• Raised $69.7 million in net proceeds through a follow-on stock offering in February 2025.
• Ended an exclusive distribution agreement for DIXI Medical products on December 31, 2025, to focus on core operations.

The Power of Patient Data

NeuroPace manages a large brain activity data set to help doctors improve patient care. It is also developing tools that use artificial intelligence to optimize treatment settings for individual patients.

Revenue Growth and Financial Facts

• Revenue was $44.8 million for the six-month period ended June 30, 2026, up 19% year over year.
• Net loss from continuing operations was $12.9 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and short-term investments totaled $51.7 million as of June 30, 2026.
• Outstanding debt under the term loan facility was $59.0 million as of June 30, 2026.

Bottom Line

NeuroPace has transitioned from a research-focused firm to a commercial provider of brain-responsive technology. By focusing on data-driven outcomes and expanding its clinical reach, the company seeks to change the standard of care for epilepsy.